OBJECTIVE: To examine the effects of fenofibrate (160mg/d) therapy on fasting and
postprandial cytokine production in subjects with metabolic syndrome and …

OBJECTIVE—The aim of this study was to determine the effects of fenofibrate (160 mg/day)
on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in …

Background: Atherosclerosis is the leading cause of death in developed countries. Although
the mechanisms that underlie this process are not well defined, it has been proposed that …

PURPOSE: To determine whether hypertriglyceridemia is associated with systemic
inflammation, which may contribute to the increased cardiovascular risk in patients who …

The aim of this study was to compare the action of fenofibrate on monocyte cytokine release
between patients with isolated mixed dyslipidemia and dyslipidemia coexisting …

Context: Fenofibrate is a peroxisome proliferator-activated receptor α agonist widely used in
clinical practice, but its mechanism of action is incompletely understood. Objective: The aim …

The goal was to investigate the effect of micronized fenofibrate, a hypolipidemic drug, on
inflammatory markers and proinsulin in patients with type 2 diabetes who had …

Background: Fasting and post‐prandial hypertriglyceridemia have been associated with
endothelial dysfunction. Objective: To investigate the effects of a 3‐month treatment with …

BACKGROUND: We investigated effects of fenofibrate therapy on endothelial dysfunction
and adipocytokine profiles. METHODS: A randomized, single-blind, placebo-controlled …

Fibrates and omega‐3 fatty acids have been used for many years in the treatment of
increased triglyceride levels. Unfortunately, pleiotropic effects of these agents in patients …